Genitourinary syndrome of menopause
Genitourinary syndrome of menopause is the chronic, progressive constellation of vulvovaginal and lower urinary tract symptoms caused by estrogen deficiency, presenting with vaginal dryness, dyspareunia, and recurrent urinary symptoms in menopausal women. It is a clinical diagnosis treated first with nonhormonal moisturizers and lubricants, then low-dose vaginal estrogen, with ospemifene or vaginal prasterone reserved as second-line options.
- Topic reviewThe full article, organized the way the exam asks it.
- ABIM-format MCQsVignettes with an explanation for every wrong answer.
- Key factsThe numbers and thresholds worth memorizing, up front.
- AI tutorMedBrain answers the question you're stuck on.
What this article covers
- Overview
Genitourinary syndrome of menopause (GSM) is the estrogen-deficiency syndrome of the vulva, vagina, and lower urinary tract: falling estrogen thins and de-vascularizes the genitourinary epithelium…
- Epidemiology
Affects a substantial proportion of postmenopausal women, with prevalence rising the longer a woman is past menopause.
- Risk factors
Natural or surgical menopause: the dominant driver, from loss of ovarian estrogen production.
- Pathophysiology
Estrogen deficiency removes trophic support from the vaginal, vulvar, and lower urinary tract epithelium: estrogen receptors are dense in these tissues, and withdrawal thins the mucosa.
- Clinical features
Vaginal dryness is the most common and earliest symptom, reported by most affected women.
- Differential diagnosis
Vulvovaginal candidiasis: itching with thick, white, curdy discharge and vulvar edema/excoriation; wet mount shows yeast, hyphae, or pseudohyphae, unlike the atrophic, low-inflammation picture of GSM.
- Diagnosis
GSM is a clinical diagnosis: history of a hypoestrogenic state (menopause, lactation, or antiestrogen therapy) plus the characteristic symptom triad of vaginal dryness, dyspareunia, and urinary…
- Management
Start with nonhormonal, first-line therapy for all patients regardless of severity: as-needed vaginal lubricants at the time of intercourse plus a vaginal moisturizer used regularly (for example…
- Complications
Progressive introital and vaginal stenosis from unopposed atrophic narrowing, causing worsening dyspareunia and, if severe, difficulty tolerating pelvic examination.
- Prognosis
Symptoms reliably improve with appropriate, sustained therapy: most women have significant relief of dryness, dyspareunia, and urinary symptoms within weeks of starting vaginal moisturizers or low-dose vaginal estrogen.
- Prevention
Counsel all women approaching or past menopause about expected genitourinary changes so symptoms are reported early rather than assumed to be an unavoidable consequence of aging.
Read the whole article
Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.
Related articles
- Menopause
Menopause is the permanent cessation of menses from ovarian follicular depletion, confirmed retrospectively after 12 months of amenorrhea around a mean age of 51 years. Management centers on treating moderate to severe vasomotor symptoms with the lowest effective dose of hormone therapy in appropriately selected candidates, alongside bone and cardiovascular risk assessment.
- Dyspareunia
Dyspareunia is triaged by pain timing and location, not treated as one disease: superficial pain at the introitus on entry points to vulvovaginal atrophy, infection, vulvodynia, or vaginismus, while deep pain with penetration points to endometriosis, pelvic inflammatory disease, or a pelvic mass, and each branch has its own diagnostic and treatment pathway.
- Vulvovaginal candidiasis
Candida vulvovaginitis presents with vulvar itching, burning, and thick curdy white discharge at a normal vaginal pH; uncomplicated disease clears with a single 150 mg oral fluconazole dose or a short topical azole course, while complicated or recurrent disease needs a longer induction course followed by suppressive therapy.
- Bacterial vaginosis
Bacterial vaginosis is a polymicrobial dysbiosis of the vagina caused by loss of lactobacilli and anaerobic overgrowth, diagnosed clinically by the Amsel criteria and treated with oral or intravaginal metronidazole or clindamycin.
- Trichomonas vaginalis infection
Trichomonas vaginalis is a flagellated protozoan sexually transmitted infection that presents with malodorous frothy yellow-green discharge and a strawberry cervix but is frequently asymptomatic, especially in men. Diagnosis rests on nucleic acid amplification testing of vaginal secretions, and treatment is a single 2 g oral dose of metronidazole or tinidazole with partner treatment and retesting in 3 months for high reinfection rates.
- Vulvar lichen sclerosus
Vulvar lichen sclerosus is a chronic inflammatory dermatosis causing porcelain-white atrophic plaques, itching, and scarring of the vulva, confirmed by biopsy and treated with an ultrapotent topical corticosteroid to relieve symptoms and reduce the lifelong risk of vulvar squamous cell carcinoma.
- Urinary tract infections (UTIs), including pyelonephritis
Urinary tract infection spans uncomplicated cystitis, presenting with dysuria, frequency, and suprapubic pain, through pyelonephritis, presenting with fever, flank pain, and costovertebral angle tenderness, most often from ascending Escherichia coli. Uncomplicated cystitis is treated empirically without culture using nitrofurantoin, trimethoprim-sulfamethoxazole, or fosfomycin, while pyelonephritis requires a pre-treatment urine culture and empiric fluoroquinolone or cephalosporin therapy, escalated to hospitalization and broader parenteral coverage for hemodynamic instability, obstruction, or failure to improve.
- Evaluation of vaginal discharge
Abnormal vaginal discharge is triaged at the bedside with vaginal pH, the amine whiff test, and saline/KOH microscopy, and treated with metronidazole for bacterial vaginosis or trichomoniasis, fluconazole or clotrimazole for candidiasis, and ceftriaxone plus doxycycline for cervicitis.
- Breast cancer
Breast cancer is a malignancy of ductal or lobular epithelium, most often presenting as a firm, painless mass in the upper outer quadrant. Diagnosis rests on core needle biopsy with estrogen, progesterone, and HER2 receptor testing, and first-line treatment pairs breast-conserving surgery or mastectomy with sentinel node biopsy, radiation, and receptor-guided systemic therapy such as tamoxifen or trastuzumab.